INTRODUCTION
Replication-defective retroviral vectors are widely used for ex vivo gene transfer. For clinical applications, ex vivo protocols offer the means of monitoring and controlling for the appearance of replication-competent retroviruses that may emerge as a result of recombination events and compromise safety (Farson et al., 1999) . Generally, ex vivo gene transfer schemes suffer from low gene transfer efficiency and additional steps may be needed to enrich for transduced cells in the transplant (Journal of Gene Medicine Web site). In cases where the transferred gene offers a direct selective advantage in the recipients, engraftment and proliferation may be favored (Parkman et al., 2000) . However, in other cases engraftment of the genetically modified cells is disfavored and may require treatments leading to cell reduction or immunosuppression of recipients prior to transplantation.
As an alternative possibility, in vivo gene delivery may lead to a higher overall efficiency. By injection of irradiated retroviral producer cells into the bone marrow cavity of rabbits, Nelson et al. (1979) obtained in vivo gene transfer into multiple hematopoietic lineages at percentages comparable to those achieved by ex vivo transduction. By this procedure, gene delivery into the local hematopoietic environment but not into adjacent tissues was demonstrated. In vivo gene delivery by retroviral vectors undergoing multiple rounds of replication in the tissues of the recipient represents another way to achieve increased efficiency of gene transfer. Efficient in vivo delivery by replication-competent retroviral vectors might be of significant value in the dissection of differentiation and proliferation signals as well as for the testing and optimizing of effectors toward their potential later use in a clinically accepted gene transfer vehicle. However, an immune response against a vector-encoded protein(s) may prevent efficient spread of the vector in the tissues of the host, and this approach may be feasible only in immunocompromised animals or under conditions of tolerance such as in infected newborn mice (Sarzotti et al., 1996) .
We previously reported on replication-competent vectors based upon the Akv murine leukemia virus (MLV) (Jespersen et al., 1999) capable of productively replicating in mammalian cells as opposed to replication-competent vectors derived from avian viruses (Zheng and Hughes, 1999) . In this vector design, a cassette comprising an internal ribosome entry site (IRES) and a heterologous gene was inserted into the upstream part of the U3 region of the long terminal repeat (LTR). Vectors of this type were reported to replicate for several rounds in cell culture. Here we analyze the ability of an enhanced green fluorescent protein (EGFP) gene containing a vector of this type to deliver genes to hematopoietic cells after infection of newborn mice and report that more than 50% of the spleen cells are marked by EGFP during the first days after infection.
RESULTS AND DISCUSSION

Gene transfer in mice
AkvU3-EGFP is a replication-competent MLV that harbors a translational cassette consisting of the IRES of encephalomyocarditis virus and the EGFP coding region inserted in U3 (Fig. 1) . To determine whether AkvU3-EGFP can propagate in vivo, 3-to 4-day-old NIH Swiss mice were infected intraperitoneally with 10 4 colonyforming units (CFU) of AkvU3-EGFP and spleen cells were analyzed for EGFP expression at different time points postinfection. In parallel experiments, spleen cells from mice infected with Akv MLV were used as a negative control. Three separate experiments with AkvU3-EGFP were carried out with similar outcomes. For the sake of simplicity, the data for only one of them are presented here. Mononuclear cells were purified and EGFP expression was assessed in the total fraction of nonadherent spleen cells (Fig. 2, left column) . Whereas no EGFP-positive cells were detected on day 1, more than 50% of cells were EGFP-positive on day 4 and approximately 50% on day 7. After day 7, the percentage of EGFP-positive cells dropped to near detection levels.
To assess which spleen cells were infected, phenotypic identification of specific lineages was obtained using phycoerythrine (PE)-conjugated antibodies directed against specific cell surface antigens on T lymphocytes (CD 3), B lymphocytes (CD 19), and NK lymphocytes (Pan NK) (Fig. 2, middle column) . In no case did the sum of the percentages of EGFP-positive B, T, and NK cells equal 100% of the EGFP-positive cells, indicating that other cell types not recognized by the B, T, and NK cell-specific antibodies are infected by AkvU3-EGFP. The phenotypic characterization of these cells was not undertaken. However, at days 4 and 7, when EGFP-positive nonadherent spleen cells were abundant, no EGFP-positive cells were detected among the adherent spleen cells (Fig. 2, right column ).
An example of variation among animals in the pattern of EGFP expression is provided by the mouse of litter 1 analyzed at day 30. On day 12, EGFP expression had decreased to around 1% of nonadherent spleen cells in the two litters studied. Nevertheless, at day 30, the mouse from litter 1 presented 12% EGFP-positive nonadherent spleen cells and in addition this is the only animal which presented adherent EGFP-positive spleen cells (18%).
B, T, and NK spleen cells during infection
Most MLVs are pathogenic, at least in some strains of mice. Akv MLV, the parental virus of the vector used in the present study, has been reported to induce B-cell lymphomas with a latency period of around 1 year (Lovmand et al., 1998 ). An effect of MLV infection on the composition of spleen cells 6 to 10 weeks after infection has been reported (Davis et al., 1987; Storch et al., 1985) . To study the effects of genes delivered by replicationcompetent MLVs, it is therefore important to monitor the effect of virus infection per se also during the first weeks after infection.
Flow cytometry analysis allowed quantification of the total spleen B, T, and NK cell populations as well as that of EGFP-positive cells in each subpopulation (EGFPpositive B, T, and NK subpopulations as the percentage of the total nonadherent spleen cells). The histograms in Fig. 3 show the percentages of the total B, T, and NK population (first bar), the B cell population (second bar), the T cell population (third bar), and the NK population (fourth bar) for noninfected, Akv MLV-infected, and AkvU3-EGFP-infected animals. Analysis at day 1 postinfection revealed no difference in B, T, and NK cell populations of infected and noninfected animals. However, B ϩ T ϩ NK cell populations from animals infected by Akv MLV or AkvU3-EGFP decreased at day 4 (40-45%) and day 7 (30-35%) as compared with the population of noninfected animals (60%), with T and NK cells being the most affected. At later time points, the differences between infected and noninfected animals disappear, possibly with some delay for the NK cell population. Our data do not allow us to conclude whether these numbers reflect a true decrease in lymphoid cells or rather an increase in other cell types attracted by the infection (macrophages, dendritic cells, etc.).
In accordance with Fig. 2 , EGFP-positive cells are most abundant at days 4 and 7 (gray bars). For AkvU3-EGFP-infected animals, almost all B, T, and NK cells are EGFP-positive at day 4 postinfection and then EGFP expression decreases.
Vector stability
Blood viremia was monitored using both an EGFP fluorescence-based assay and a focal immunofluorescence assay (FIA) of viral envelope proteins. In both cases, titers were expressed as colony-forming units per milliliter (Table 1) . Viremia was never detected in noninfected animals nor at day 1 postinfection in Akv MLV-or AkvU3-EGFP-infected animals. EGFP-expressing viruses were detected in the blood at day 4, rose to 60-fold higher levels at day 7, and finally fell to undetectable levels at day 60 postinfection. Nevertheless, by FIA the presence of viruses could be detected until the end of the experiment in all infected animals. In Akv MLV-in- fected animals, viremia, as assayed by FIA, was detected in all cases after day 4 postinfection and remained constant over 60 days.
To detect proviral DNA in the spleen, a PCR assay was employed. Two primers which permit the amplification of a fragment of 651 bp from wild-type Akv proviruses and one of 1983 bp from AkvU3-EGFP proviruses were utilized on a set of purified spleen DNA samples (Fig. 4) . DNA from NaCl-injected (noninfected) control mice gave rise to a single PCR band that, after being subcloned in pGEMT-Easy and being sequenced, revealed an endogenous retroviral sequence differing from Akv MLV by one point mutation and lack of tandem repeats of the U3 (data not shown). In DNA samples from AkvU3-EGFPinfected mice, three bands were identified by subcloning and sequencing of several samples. The fastest migrating band found at early days after infection again corresponds to the endogenous virus band of the control samples. The band migrating slightly slower contained wild-type Akv MLV sequences and the slowest band contained Akv MLV sequences with the IRES-EGFP insert. For all three bands, sequences obtained at different days postinfection were identical. For the day 4 and day 7 samples of AkvU3-EGFP-injected mice, the IRES-EGFPcontaining band was predominant, whereas the Akv MLV wild-type band was more intense at day 12. For day 30 and day 60, only the Akv wild-type band was detected. By using one EGFP-specific primer and the primer located in env, we were able to amplify PCR bands corresponding to the expected size for a complete IRES-EGFP cassette from all DNA samples from spleens. However, the bands from day 60 and day 30 were not as intense as samples of earlier time points, indicating that the level of intact AkvU3-EGFP had dropped.
In our earlier studies in cell culture, multiple passages of this type of replication-competent vector led to the appearance of variants with deletions in the heterologous gene cassette and, eventually, to the dominance of these deletion variants with presumed better replication fitness. After elimination of the initially Akv-EGFP-infected spleen cells, new cells may be infected by viruses that have already lost the EGFP cassette. Considering that cells of the spleen are known to turn over rapidly (Rolink et al., 1998 ) the in vivo pattern may comply with our earlier in vitro observations. Moreover, receptor interference will prevent superinfection by EGFP-harboring vectors of cells already infected by a cassette deletion variant. Without a specific selective pressure operating in favor of maintaining the transgene in the vectors or in the cells, the problem of the appearance of deletion variants with a replication advantage will persist. The results reported here show some animal to animal variations with respect to transgene expression. One animal analyzed at day 30 after infection showed 12% EGFPpositive cells among the nonadherent spleen cells while a second animal showed none. The latter animal was also the only one that showed significant EGFP expression in adherent spleen cells. A similar animal to animal variation was seen in a second experiment (data not shown). Note. One mouse per group was sacrificed at regular intervals and viremia was assayed in duplicate (CFU/ml). Viremia was not detected in noninfected mice.
a Cells infected by either EGFP-expressing or non-EGFP-expressing viruses were assayed by FIA using a specific anti-envelope glycoprotein 83A25 monoclonal antibody.
b Cells infected by EGFP-expressing retroviruses were assayed using direct EGFP fluorescence.
FIG. 4.
PCR amplification from spleen DNA of provirus sequences containing the IRES-EGFP insert. Lane C corresponds to control DNA from mice injected with a NaCl solution. Lanes 1 and 2 correspond to litters 1 and 2, respectively.
Perspectives
Vehicles for stable transfer of genes into hematopoietic cells are derived mainly from retroviruses of the MLV group. Even though the tumorigenic specificity of individual strains may be narrower the MLVs are able to infect a broad range of hematopoietic cells. Using EGFP as a reporter gene and the spleen as a read-out organ, the present study reports on efficient gene delivery into mouse hematopoietic cells in vivo. The EGFP gene is delivered by an Akv MLV-based vector that harbors all genes needed for viral replication and is able to undergo multiple rounds of infection in the animal.
Despite the appearance of wild-type viruses at later stages and the need to assess possible effects caused by the viruses, the gene delivery model presented here should be valuable for studying the effect of transgene expression in spleen cells in a time window of 1 to 2 weeks. Moreover, improvements in the vector and delivery scheme may result in the prolongation of the time window of efficient transgene expression. A model for efficient in vivo gene delivery may serve a number of research applications in which efficiency of gene delivery rather than site-specific or time-controlled expression is of importance. Among these are applications in relation to the development of gene transfer systems, analysis of the function of a gene product in an in vivo setting, and the test and optimization of protein-based therapeutics.
MATERIALS AND METHODS
Cell culture
NIH3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing Glutamax-1 (Gibco) supplemented with 10% newborn calf serum and 1% penicillin/streptomycin (Gibco). BOSC 23 (Pear et al., 1993) and Mus dunni embryo fibroblast cells were grown in DMEM containing Glutamax-1 and supplemented with 10% fetal calf serum. Prior to transfection, the BOSC 23 cells were selected in HAT medium as described (Jespersen et al., 1999) .
Vectors
AkvU3-EGFP is isogenic to the previously described AkvBi-EGFP (Jespersen et al., 1999) except that the spacer sequence from the 3Ј end of the IRES element, IRES start codon 10 (codon in parentheses), to the translational start codon of the EGFP gene has been changed from (ATT)GCCGCGTGTGGCCTCGAACACCGAGCGACCCTGC-AGCCGCGGTCGACATGG to the spacer proposed by Morgan et al. (1992) , (ATA)ATACCATG. As assayed by flow cytometry analysis, AkvU3-EGFP was found to express EGFP at a 10-fold higher level than the original AkvBi-EGFP construct. The AkvU3-EGFP producer line was generated as described by Jespersen et al. (1999) and expanded in cell culture, and aliquots were stored in liquid nitrogen. Virus harvested from these cells was used for injection of mice.
Assay of viruses
Production and titer assays of Akv MLV and AkvU3-EGFP stocks were carried out as follows. Virus-producing cells were cultured at confluence for 3 days. Viral supernatants were harvested and filtered through 0.45-m-pore-size filters and serial dilutions were added in duplicate to M. dunni cells seeded at a density of 2 ϫ 10 3 cells/well of 96-well plates (Nunc, Roskilde, Denmark) the day before in the presence of 8 g/ml polybrene. The culture medium was changed on the following day and, when confluent, cells infected by AkvU3-EGFP were scored using direct EGFP fluorescence and cells infected by Akv MLV were scored by FIA (Sitbon et al., 1985) using the specific anti-envelope glycoprotein 83A25 monoclonal antibody (Evans et al., 1990) . The antibody was revealed using an anti-mouse immunoglobulin fluorescein isothiocyanate-conjugated rabbit antiserum (Sigma, St. Louis, MO).
Viremia
Blood viremia was determined by duplicate infections of M. dunni cells using serial dilutions of infected animal sera in the direct EGFP fluorescence assay and the indirect focal immunofluorescence assay.
Mice and viral infection
NIH Swiss mice were purchased from CERJ (France). Animals were maintained with their mother for up to 3 weeks of age. Two litters of 3-or 4-day-old animals were injected intraperitoneally with 100 l of AkvU3-EGFP (1 ϫ 10 5 CFU/ml) and animals from 1 litter were injected intraperitoneally with 100 l (1 ϫ 10 5 CFU/ml) of Akv MLV. Finally, noninfected mice were used as a control. Mice were bled for determination of viremia; then, the spleen was removed for DNA preparation and for purification of mononuclear cells.
Flow cytometry
For isolation of mononuclear cells, spleens were excised and pooled using six spleens of each litter at day 1 postinfection, four spleens of each litter at day 4 postinfection, and two spleens of each litter at days 7 and 12. One spleen was used at days 30 and 60 postinfection. Spleens were placed in a petri dish with 10 ml of RPMI medium and crushed with a 1-ml syringe (piston) and then splenocytes were detached by pipetting up and down. Cells were centrifuged at 490 g at 18°C for 5 min and the pellet was resuspended in RPMI medium (Gibco) plus erythrocyte lysis buffer (32 ϫ 10 Ϫ6 M EDTA, 0.15 M NH 4 Cl, 0.01 M KHCO 3 ). After centrifugation at 490 g at 18°C for 5 min, cells were incubated at 37°C in the presence of 5% CO 2 for 2 h, to remove adherent cells essentially, including dendritic cells and macrophages. Cells in suspension were centrifuged and resuspended in 8 ml of Hanks' balanced salt solution (BioWhittaker Europe) containing phenol red and 4 ml of Ficoll solution (Ficoll-Paque Plus, Amersham) at room temperature. The mixture was centrifuged at 330 g at 18°C for 20 min and lymphocytes were collected from the interphase and washed, first, with 40 ml of PBS (0.15 M NaCl, 0.01 M sodium phosphate, pH 7) and then twice with 30 ml of RPMI medium. Monoclonal (PE)-conjugated anti-mouse CD3, anti-mouse CD19, and anti-mouse PAN NK (Pharmingen) were used to assay for the percentages of B, T, and NK cells, respectively, in the spleen of infected and noninfected animals by flow cytometry using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). EGFP-positive cells were detected by direct fluorescence flow cytometry. Ten thousand cells were analyzed per experiment. Green fluorescence (EGFP) was measured through a 530-nm/30-nm bandpass filter and orange fluorescence (PE) was measured through a 585-nm/42-nm bandpass filter after illumination with an argon ion laser tuned at 488 nm. Lymphocytes (B, T, and NK) were incubated with specific antibodies for 30 min at 4°C and then washed in PBS before flow cytometry analysis.
PCR
DNA was isolated from spleens as previously described (Gross-Bellard et al., 1973) . PCR amplification was performed in 25 l PCR buffer containing 100 to 400 ng of purified spleen DNA, 25 pmol of each primer, 0.2 mM dNTPs, and 0.5 U of AmpliTaqGold DNA polymerase (Perkin-Elmer). After an initial AmpliTaqGold activation step of 9 min at 94°C, the PCR was as follows: 40 cycles of 1.2 min at 94°C, 1.2 min at 60°C, and 3 min at 72°C. The 40 cycles were followed by an incubation of 7 min at 72°C. The two oligonucleotides used as primers match sequences located outside the IRES-EGFP insert at the 3Ј end of the envelope gene (position 7562 to 7590, CAACAAGGGTGGTTTGAAGGGCTGTTTAA) of the Akv MLV RNA genome and in the U3 region (position 8185 to 8213, AGGCTTGGGGTTGATCCCCGGTCATCTGG) (Van Beveren, 1985) . These two primers amplify a DNA fragment of 651 bp from wild-type Akv MLV and a fragment of 1983 bp from AkvU3-EGFP.
